Cyclopharm Past Earnings Performance
Past criteria checks 0/6
Cyclopharm's earnings have been declining at an average annual rate of -19.3%, while the Medical Equipment industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 13.7% per year.
Key information
-19.3%
Earnings growth rate
-12.9%
EPS growth rate
| Medical Equipment Industry Growth | 5.8% |
| Revenue growth rate | 13.7% |
| Return on equity | -14.6% |
| Net Margin | -17.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash
Oct 28
Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?
Apr 18Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth
Mar 31Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Oct 17Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Jun 09Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher
Mar 06Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation
Mar 02We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth
Oct 22Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates
Jun 29Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being
Apr 27Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic
Mar 01Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment
Feb 07Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?
Jan 02We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate
Dec 06Revenue & Expenses BreakdownBeta
How Cyclopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 27 | -5 | 21 | 4 |
| 30 Sep 23 | 28 | -6 | 20 | 5 |
| 30 Jun 23 | 29 | -7 | 19 | 6 |
| 31 Mar 23 | 27 | -7 | 19 | 5 |
| 31 Dec 22 | 25 | -7 | 19 | 3 |
| 30 Sep 22 | 24 | -5 | 18 | 2 |
| 30 Jun 22 | 23 | -4 | 18 | 1 |
| 31 Mar 22 | 21 | -4 | 17 | 1 |
| 31 Dec 21 | 20 | -5 | 17 | 2 |
| 30 Sep 21 | 20 | -5 | 16 | 2 |
| 30 Jun 21 | 20 | -4 | 16 | 3 |
| 31 Mar 21 | 19 | -5 | 15 | 3 |
| 31 Dec 20 | 18 | -6 | 14 | 4 |
| 30 Sep 20 | 17 | -6 | 14 | 4 |
| 30 Jun 20 | 16 | -6 | 13 | 4 |
| 31 Mar 20 | 17 | -4 | 13 | 4 |
| 31 Dec 19 | 17 | -3 | 12 | 4 |
| 30 Sep 19 | 16 | -3 | 11 | 4 |
| 30 Jun 19 | 16 | -2 | 10 | 4 |
| 31 Mar 19 | 16 | -1 | 10 | 4 |
| 31 Dec 18 | 16 | 0 | 9 | 3 |
| 30 Sep 18 | 16 | 0 | 9 | 3 |
| 30 Jun 18 | 16 | -1 | 9 | 3 |
| 31 Mar 18 | 16 | -1 | 9 | 3 |
| 31 Dec 17 | 16 | -2 | 9 | 3 |
| 30 Sep 17 | 15 | -1 | 8 | 3 |
| 30 Jun 17 | 14 | -1 | 8 | 2 |
| 31 Mar 17 | 15 | 0 | 8 | 2 |
| 31 Dec 16 | 15 | 1 | 8 | 1 |
| 30 Sep 16 | 14 | 3 | 7 | 1 |
| 30 Jun 16 | 14 | 5 | 7 | 1 |
| 31 Mar 16 | 13 | 5 | 7 | 1 |
| 31 Dec 15 | 13 | 5 | 6 | 1 |
| 30 Sep 15 | 12 | 4 | 6 | 1 |
| 30 Jun 15 | 11 | 3 | 6 | 1 |
| 31 Mar 15 | 11 | 4 | 7 | 1 |
| 31 Dec 14 | 12 | 4 | 7 | 0 |
| 30 Sep 14 | 13 | -2 | 7 | 0 |
| 30 Jun 14 | 14 | -8 | 8 | 0 |
| 31 Mar 14 | 13 | -9 | 8 | 0 |
| 31 Dec 13 | 12 | -10 | 8 | 0 |
| 30 Sep 13 | 12 | -6 | 7 | 0 |
| 30 Jun 13 | 11 | -1 | 7 | 0 |
Quality Earnings: CYC is currently unprofitable.
Growing Profit Margin: CYC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYC is unprofitable, and losses have increased over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare CYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Return on Equity
High ROE: CYC has a negative Return on Equity (-14.57%), as it is currently unprofitable.